 I-Mab NASDAQ:IMAB, a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders, today announced the opening of its Hong Kong office. The newest addition expands I-Mabs existing footprint in Shanghai, Beijing and Rockville, MD. The Hong Kong office, located in Central, will serve as a regional hub for capital markets and investor relations activities for I-Mab. 